# US 2004/0024009 A1 · Dihydropyrazolo[3,4-d]thieno-[2,3-B]pyridinone inhibitors of B7-1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0024009 A1
- Document ID: US20040024009A1
- Status: Published application
- Kind: A1
- Application number: 10/629,022
- Filed: 2003-07-28
- Published: 2004-02-05
- Earliest claimed: 2002-07-29
- Assignees: Wyeth
- Inventors: Neal Jeffrey Green; Lihren Chen; Steve Yikkai Tam
- Web page: https://patentgrep.com/patent/US20040024009A1

## CPC

- C07D 495/14: Ortho-condensed systems
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides a compound of formula I and the use thereof for the immunotherapeutic treatment of transplant rejection, autoimmune disease or graft vs. host disease. 1

## Claims

### Claim 1

A compound of formula I
15
wherein
R1 and R2 are each independently H, C1-C10alkyl optionally substituted with one or more halogen, hydroxy, C1-C4alkoxy, CO2R6, CONR7R8, C3-C7cycloalkyl or optionally substituted phenyl groups, or
phenyl optionally substituted with one to three halogen, hydroxy, C1-C6haloalkyl, C1-C4alkoxy, CO2R9, NR10R11 or CN groups;
R3 is H, C1-C6alkyl optionally substituted with a phenyl, naphthyl or heteroaryl group each group optionally substituted with one to three C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxy, hydroxy, CHO, NO2, CN, CO2R12 or NR13R14 groups,
phenyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CONR15R16, SO2NR15R16, CO2R17, NR18R19 or CH2CO2R20 groups,
naphthyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CO2R17, NR18R19 or CH2CO2R20 groups,
C5-C7cycloheteroalkyl optionally substituted with one to three halogen, NO2, CN, C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxy, CO2R17 or NR18R19 groups, or
heteroaryl optionally substituted with one to three halogen, NO2, CN, C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxy, CO2R17 or NR18R19 groups;
R4 is phenyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR26, SO2NR21R22, CO2R23 or NR24R25 groups,
cycloheteroalkyl optionally substituted with one or more halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR26, SO2NR21,R22, CO2R23 or NR24R25 groups, or
heteroaryl optionally substituted with one or more halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR26, SO2NR21R22, CO2R23 or NR24R25 groups;
R5 is H, C1-C3alkyl or haloalkyl;
R6, R9, R12, R17, R20, R26 and R27 are each independently H or a C1-C6alkyl, C3-C7 cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted;
n is 0 or an integer of 1 or 2;
R7, R8, R10, R11, R13, R14, R18, R19, R21, R22, R24 and R25 are each independently H or a C1-C6alkyl, C3-C7cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted or each of R7 and R8 or R10 and R11 or R13 and R14 or R18 and R19 or R21 and R22 or R24 and R25 may be taken together with the nitrogen atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S; and
R15 and R16 are each independently H, NH2, CH2CH2OCH2CH2OCH2CH2NH2 or a C1-C6alkyl group optionally substituted with one or two CN, OR5, NR13R14, CO2R17 or C3-C7cycloalkyl group;
phenyl optionally substituted with one or two halogen, OR5, CN, NR13R14, CO2R17, COR27, an optionally substituted C1-C8alkyl group or an optionally substituted C2-C6alkenyl group;
benzyl optionally substituted with one or two halogen, OR5, COR27 or a C1-C6alkyl group optionally substituted with one OR5 or
pyridinyl optionally substituted with one or two halogen, OR5, NR13R14 or CO2R17 groups or
R15 and R16 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing one double bond, a benzofused ring or an additional heteroatom selected from O, N or S; or
the stereoisomers thereof or the pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

The compound according to claim 1 wherein R3 is an optionally substituted phenyl or heteroaryl group.

### Claim 3 (depends on 1)

The compound according to claim 1 wherein R1 and R2 are H.

### Claim 4 (depends on 1)

The compound according to claim 1 wherein R4 is a C5-C7cycloheteroalkyl, heteroaryl or phenyl group each optionally substituted with one or two halogen, CN, NO2, CF3, methoxy, carboxy or SOR26 groups.

### Claim 5 (depends on 2)

The compound according to claim 2 wherein R1 and R2 are H.

### Claim 6 (depends on 2)

The compound according to claim 2 wherein R4 is a thienyl, pyridyl or phenyl group, each optionally substituted with one or two halogen, CN, NO2, CF3, methoxy, carboxy or SOCH3 groups.

### Claim 7 (depends on 3)

The compound according to claim 3 wherein R3 is a phenyl group substituted with one or two halogen, CONR15R16 or SO2NR15R16 groups.

### Claim 8 (depends on 7)

The compound according to claim 7 wherein R4 is a phenyl group substituted with one NO2 or CF3 group.

### Claim 9 (depends on 1)

The compound according to claim 1 selected from the group consisting of:
2-(4-chlorophenyl)-4-[3-(trifluoromethyl)phenyl]-1,2-dihydro-3H-pyrazolo[3,4-d]thieno[2,3-b]pyridin-3-one;
2-(4-fluorophenyl)-4-[3-(trifluoromethyl)phenyl]-1,2-dihydro-3H-pyrazolo-[3,4-d]thieno[2,3-b]pyridin-3-one;
N-(3,4-dihydroxybenzyl)-3-{3-oxo-4-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrazolo[3,4-d]thieno[2,3-b]pyridin-2(1H)-yl}benzamide;
N-[3-(1-hydroxyethyl)phenyl]-4-{3-oxo-4-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrazolo[3,4-d]thieno[2,3-b]pyridin-2(1H)-yl}benzamide;
({[4-(6-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-dihydropyrazolo[3,4-d]thieno[2,3-b]pyridin-2-(1H)-yl)phenyl]sulfonyl}amino)acetic acid;
the stereoisomers thereof; or the pharmaceutically acceptable salts thereof.

### Claim 10

A method for the treatment of an immune disorder related to or affected by the immune regulatory protein B7-1 which comprises providing a patient in need thereof an immunotherapeutically effective amount of a compound of formula I
16
wherein
R1 and R2 are each independently H, C1-C10alkyl optionally substituted with one or more halogen, hydroxy, C1-C4alkoxy, CO2R6, CONR7R8, C3-C7cycloalkyl or optionally substituted phenyl groups, or
phenyl optionally substituted with one to three halogen, hydroxy, C1-C6haloalkyl, C1-C4alkoxy, CO2R9, NR10R11 or CN groups;
R3 is H, C1-C6alkyl optionally substituted with a phenyl, naphthyl or heteroaryl group each group optionally substituted with one to three C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxy, hydroxy, CHO, NO2, CN, CO2R12 or NR13R14 groups,
phenyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CONR15R16, SO2NR15R16, CO2R17, NR18R19 or CH2CO2R20 groups,
naphthyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CO2R17, NR18R19 or CH2CO2R20 groups,
C5-C7cycloheteroalkyl optionally substituted with one to three halogen, NO2, CN, C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxy, CO2R17 or NR18R19 groups, or
heteroaryl optionally substituted with one to three halogen, NO2, CN, C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxy, CO2R17 or NR18R19 groups;
R4 is phenyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR26, SO2NR21R22, CO2R23 or NR24R25 groups,
cycloheteroalkyl optionally substituted with one or more halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR26, SO2NR21,R22, CO2R23 or NR24R25 groups, or
heteroaryl optionally substituted with one or more halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR26, SO2NR21R22, CO2R23 or NR24R25 groups;
R5 is H, C1-C3alkyl or haloalkyl;
R6, R9, R12, R17, R20, R26 and R27 are each independently H or a C1-C6alkyl,
C3-C7 cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted;
n is 0 or an integer of 1 or 2;
R7, R8, R10, R11, R13, R14, R18, R19, R21, R22, R24 and qR25 are each independently H or a C1-C6alkyl, C3-C7cycloalkyl, C1-C6haloalkyl, phenyl,
C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted or each of R7 and R8 or R10 and R11 or R13 and R14 or R18 and R19 or R21 and R22 or R24 and R25 may be taken together with the nitrogen atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S; and
R15 and R16 are each independently H, NH2, CH2CH2OCH2CH2OCH2CH2NH2 or a C1-C6alkyl group optionally substituted with one or two CN, OR5, NR13R14, CO2R17 or C3-C7cycloalkyl group;
phenyl optionally substituted with one or two halogen, OR5, CN, NR13R14, CO2R17, COR27, an optionally substituted C1-C8alkyl group or an optionally substituted C2-C6alkenyl group;
benzyl optionally substituted with one or two halogen, OR5, COR27 or a C1-C6alkyl group optionally substituted with one OR5 or
pyridinyl optionally substituted with one or two halogen, OR5, NR13R14 or CO2R17 groups or
R15 and R16 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing one double bond, a benzofused ring or an additional heteroatom selected from O, N or S; or
the stereoisomers thereof or the pharmaceutically acceptable salts thereof.

### Claim 11 (depends on 10)

The method according to claim 10 wherein said disorder is transplant rejection.

### Claim 12 (depends on 10)

The method according to claim 10 wherein said disorder is an autoimmune disease.

### Claim 13 (depends on 10)

The method according to claim 10 wherein said disorder is graft vs. host disease.

### Claim 14 (depends on 12)

The method according to claim 12 wherein said disease is multiple sclerosis or rheumatoid arthritis.

### Claim 15

A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I
17
wherein
R1 and R2 are each independently H, C1-C10alkyl optionally substituted with one or more halogen, hydroxy, C1-C4alkoxy, CO2R6, CONR7R8, C3C7cycloalkyl or optionally substituted phenyl groups, or
phenyl optionally substituted with one to three halogen, hydroxy, C1-C6haloalkyl, C1-C4alkoxy, CO2R9, NR10R11 or CN groups;
R3 is H, C1-C6alkyl optionally substituted with a phenyl, naphthyl or heteroaryl group each group optionally substituted with one to three C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxy, hydroxy, CHO, NO2, CN, CO2R12 or NR13R14 groups,
phenyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CONR15R16, SO2NR15R16, CO2R17, NR18R19 or CH2CO2R20 groups,
naphthyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CO2R17, NR18R19 or CH2CO2R20 groups,
C5-C7cycloheteroalkyl optionally substituted with one to three halogen, NO2, CN, C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxy, CO2R17 or NR18R19 groups, or
heteroaryl optionally substituted with one to three halogen, NO2, CN, C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxy, CO2R17 or NR18R19 groups;
R4 is phenyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR26, SO2NR21R22, CO2R23 or NR24R25 groups,
cycloheteroalkyl optionally substituted with one or more halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR26, SO2NR21,R22, CO2R23 or NR24R25 groups, or
heteroaryl optionally substituted with one or more halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR26, SO2NR21R22, CO2R23 or NR24R25 groups;
R5 is H, C1-C3alkyl or haloalkyl;
R6, R9, R12, R17, R20, R26 and R27 are each independently H or a C1-C6alkyl,
C3-C7 cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted;
n is 0 or an integer of 1 or 2;
R7, R8, R10, R11, R13, R14, R18, R19, R21, R22, R24 and R25 are each independently H or a C1-C6alkyl, C3-C7cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted or each of R7 and R8 or R10 and R11 or R13 and R14 or R18 and R19 or R21 and R22 or R24 and R25 may be taken together with the nitrogen atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S; and
R15 and R16 are each independently H, NH2, CH2CH2OCH2CH2OCH2CH2NH2 or a C1-C6alkyl group optionally substituted with one or two CN, OR5, NR13R14, CO2R17 or C3-C7cycloalkyl group;
phenyl optionally substituted with one or two halogen, OR5, CN, NR13R14, CO2R17, COR27, an optionally substituted C1-C8alkyl group or an optionally substituted C2-C6alkenyl group;
benzyl optionally substituted with one or two halogen, OR5, COR27 or a C1-C6alkyl group optionally substituted with one OR5 or
pyridinyl optionally substituted with one or two halogen, OR5, NR13R14 or CO2R17 groups or
R15 and R16 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing one double bond, a benzofused ring or an additional heteroatom selected from O, N or S; or
the stereoisomers thereof or the pharmaceutically acceptable salts thereof.

### Claim 16 (depends on 15)

The composition according to claim 15 having a formula I compound wherein R3 is an optionally substituted phenyl, thienyl or pyridyl group.

### Claim 17 (depends on 16)

The composition according to claim 16 having a formula I compound wherein R1 and R2 are H.

### Claim 18 (depends on 17)

The composition according to claim 17 having a formula I compound wherein R4 is a thienyl, pyridyl or phenyl group each optionally substituted with one or two halogen, CN, NO2, CF3, methoxy, carboxy or SOCH3 groups.

### Claim 19 (depends on 18)

The composition according to claim 18 having a formula I compound wherein R3 is a phenyl group substituted with one or two halogen, CONR15R16 or SO2NR15R16 groups.

### Claim 20

A process for the preparation of a compound of formula I
18
wherein
R1 and R2 are each independently H, C1-C10alkyl optionally substituted with one or more halogen, hydroxy, C1-C4alkoxy, CO2R6, CONR7R8, C3-C7cycloalkyl or optionally substituted phenyl groups, or
phenyl optionally substituted with one to three halogen, hydroxy, C1-C6haloalkyl, C1-C4alkoxy, CO2R9, NR10R11 or CN groups;
R3 is H, C1-C6alkyl optionally substituted with a phenyl, naphthyl or heteroaryl group each group optionally substituted with one to three C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxy, hydroxy, CHO, NO2, CN, CO2R12 or NR13R14 groups,
phenyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CONR15R16, SO2NR15R16, CO2R17, NR18R19 or CH2CO2R20 groups,
naphthyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CO2R17, NR18R19 or CH2CO2R20 groups,
C5-C7cycloheteroalkyl optionally substituted with one to three halogen, NO2, CN, C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxy, CO2R17 or NR18R19 groups, or
heteroaryl optionally substituted with one to three halogen, NO2, CN, C1-C6alkyl, C1-C6haloalkyl, C1-C4alkoxy, CO2R17 or NR18R19 groups;
R4 is phenyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR26, SO2NR21R22, CO2R23 or NR24R25 groups,
cycloheteroalkyl optionally substituted with one or more halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR26, SO2NR21,R22, CO2R23 or NR24R25 groups, or
heteroaryl optionally substituted with one or more halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR26, SO2NR21R22, CO2R23 or NR24R25 groups;
R5 is H, C1-C3alkyl or haloalkyl;
R6, R9, R12, R17, R20, R26 and R27 are each independently H or a C1-C6alkyl, C3-C7 cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted;
n is 0 or an integer of 1 or 2;
R7, R8, R10, R11, R13, R14, R18, R19, R21, R22, R24 and R25 are each independently H or a C1-C6alkyl, C3-C7cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted or each of R7 and R8 or R10 and R11 or R13 and R14 or R18 and R19 or R21 and R22 or R24 and R25 may be taken together with the nitrogen atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S; and
R15 and R16 are each independently H, NH2, CH2CH2OCH2CH2OCH2CH2NH2 or a C1-C6alkyl group optionally substituted with one or two CN, OR5, NR13R14, CO2R17 or C3-C7cycloalkyl group;
phenyl optionally substituted with one or two halogen, OR5, CN, NR13R14, CO2R17, COR27, an optionally substituted C1-C8alkyl group or an optionally substituted C2-C6alkenyl group;
benzyl optionally substituted with one or two halogen, OR5, COR27 or a C1-C6alkyl group optionally substituted with one OR5 or
pyridinyl optionally substituted with one or two halogen, OR5, NR13R14 or CO2R17 groups or
R15 and R16 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing one double bond, a benzofused ring or an additional heteroatom selected from O, N or S; or
which process comprises reacting a compound of formula VI
19
wherein R1, R2 and R4 are described hereinabove with a hydrazine, R3NHNH2, to give a 3-hydrazinylthieno-[2,3-b]pyridine intermediate; and cyclizing said intermediate to give the desired compound of formula I.
